Effect of azoximer bromide on the severity of clinical manifestations in patients after SARS-CoV-2 infection

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2021-01-01 DOI:10.20953/1729-9225-2021-4-15-22

K. Kasyanenko, O. Maltsev, K. Kozlov, K. Zhdanov, I.F. Seryi

{"title":"Effect of azoximer bromide on the severity of clinical manifestations in patients after SARS-CoV-2 infection","authors":"K. Kasyanenko, O. Maltsev, K. Kozlov, K. Zhdanov, I.F. Seryi","doi":"10.20953/1729-9225-2021-4-15-22","DOIUrl":null,"url":null,"abstract":"We are now observing a constantly growing number of patients after SARS-CoV-2 infection who have active complains for more than 12 weeks. Long-term consequences of the disease significantly impair the quality of life and lead to an overburdened healthcare system, which, in the absence of effective therapeutic strategies, has a significant impact on the quality of medical care. This article discusses the main aspects of pathogenesis and clinical characteristics of post-COVID syndrome, as well as the experience of pharmacological correction of this condition. Objective. To evaluate the effect of azoximer bromide on the resolution of post-COVID syndrome by assessing the duration and severity of the main symptoms within 10 days since treatment initiation, as well as the level of chronic fatigue. Patients and methods. This study included 90 patients (both males and females). The experimental group comprised 55 individuals who received azoximer bromide for 10 days according to the package insert. The control group included 35 individuals who received no therapy. Treatment efficacy was evaluated using special questionnaires; Student's t-test and Pearson's chi-squared test were used for statistical analysis. Results. We found that significantly fewer patients from the experimental group had joint and muscle pain and headache on day 10 of the experiment than patients in the control group. Hyposmia was also less common in the experimental group then in controls by day 10. There was a significant decrease in the severity of headache, joint and muscle pain, attention impairment, dizziness, anosmia among patients receiving azoximer bromide by day 10 compared to those receiving no therapy. Patients in the experimental group also demonstrated significantly less severe fatigue compared to controls as early as day 5 of the experiment. No adverse events were registered during the study. Conclusion. Azoximer bromide demonstrated its clinical efficacy and safety in the treatment of post-COVID syndrome. Key words: SARS-CoV-2, post-COVID syndrome, fatigue, shortness of breath, smell and taste disorders","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2021-4-15-22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

We are now observing a constantly growing number of patients after SARS-CoV-2 infection who have active complains for more than 12 weeks. Long-term consequences of the disease significantly impair the quality of life and lead to an overburdened healthcare system, which, in the absence of effective therapeutic strategies, has a significant impact on the quality of medical care. This article discusses the main aspects of pathogenesis and clinical characteristics of post-COVID syndrome, as well as the experience of pharmacological correction of this condition. Objective. To evaluate the effect of azoximer bromide on the resolution of post-COVID syndrome by assessing the duration and severity of the main symptoms within 10 days since treatment initiation, as well as the level of chronic fatigue. Patients and methods. This study included 90 patients (both males and females). The experimental group comprised 55 individuals who received azoximer bromide for 10 days according to the package insert. The control group included 35 individuals who received no therapy. Treatment efficacy was evaluated using special questionnaires; Student's t-test and Pearson's chi-squared test were used for statistical analysis. Results. We found that significantly fewer patients from the experimental group had joint and muscle pain and headache on day 10 of the experiment than patients in the control group. Hyposmia was also less common in the experimental group then in controls by day 10. There was a significant decrease in the severity of headache, joint and muscle pain, attention impairment, dizziness, anosmia among patients receiving azoximer bromide by day 10 compared to those receiving no therapy. Patients in the experimental group also demonstrated significantly less severe fatigue compared to controls as early as day 5 of the experiment. No adverse events were registered during the study. Conclusion. Azoximer bromide demonstrated its clinical efficacy and safety in the treatment of post-COVID syndrome. Key words: SARS-CoV-2, post-COVID syndrome, fatigue, shortness of breath, smell and taste disorders

查看原文本刊更多论文

氮唑莫胺溴化剂对SARS-CoV-2感染后患者临床表现严重程度的影响

我们现在观察到，在感染SARS-CoV-2后，主动抱怨超过12周的患者数量不断增加。该疾病的长期后果严重损害生活质量，并导致医疗保健系统负担过重，在缺乏有效治疗策略的情况下，这对医疗保健质量产生了重大影响。本文就新冠肺炎后综合征的主要发病机制、临床特点及药物治疗经验进行了探讨。目标。通过评估治疗开始后10天内主要症状的持续时间和严重程度，以及慢性疲劳水平，评估偶氮唑海默溴化剂对covid - 19后综合征缓解的影响。患者和方法。本研究包括90例患者(包括男性和女性)。实验组由55人组成，他们根据包装说明书接受了10天的氮唑莫溴。对照组包括35名未接受任何治疗的个体。采用专用问卷评价治疗效果;采用学生t检验和Pearson卡方检验进行统计分析。结果。我们发现实验组在实验第10天出现关节、肌肉疼痛和头痛的患者明显少于对照组。到第10天，实验组的低体温现象也比对照组少。到第10天，与未接受治疗的患者相比，接受azoximer溴化治疗的患者头痛、关节和肌肉疼痛、注意力障碍、头晕、嗅觉丧失的严重程度显著降低。与对照组相比，实验组患者早在实验的第5天就表现出明显较轻的严重疲劳。研究期间未发生不良事件。结论。氮唑莫胺溴治疗新冠肺炎后综合征的临床疗效和安全性得到证实。关键词:SARS-CoV-2, covid后综合征，疲劳，呼吸短促，嗅觉和味觉障碍

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.